
Opinion|Videos|January 22, 2025
Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis
Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
- Include in your discussion the EASL 2024 abstract.
- Include in your discussion the EASL 2024 abstract.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
5



































































































